Tapinarof for Eczema: Who Had Time Off Treatment in ADORING 3?

“Time off treatment” sounds straightforward until you check who qualified and what counted as a return of disease. Tapinarof’s eczema extension study used specific rules for both.

Did tapinarof beat the cream without the drug?

The 2024 ADORING 1 and 2 report included 813 randomized participants, aged two or older, treated for eight weeks. The comparison was vehicle, the cream formulation without tapinarof.¹

The main outcome required clear or almost clear skin plus at least a two-grade improvement on an investigator’s assessment. Response was 45.4% versus 13.9% in ADORING 1 and 46.4% versus 18.0% in ADORING 2, favoring tapinarof. These were end-of-treatment results; the trials did not establish how long improvement would persist after stopping.¹

Who qualified for the reported time off treatment?

In ADORING 3, 728 participants entered an extension lasting up to 48 weeks. 378 (51.9%) entered with or achieved completely clear skin. Treatment stopped then and restarted at mild disease or worse.²³

In that selected group, the mean first interval off treatment was 79.8 consecutive days, allowing clear or almost clear skin. That does not mean symptom-free. The standard deviation was 81.4 days, showing substantial variation. Dermavant funded the trial and writing support.²³

The extension was open-label and uncontrolled. It cannot predict everyone’s interval or compare stopping with another maintenance treatment.²

How much of this evidence came from adults?

The US prescribing information identifies 124 adults and 604 children in ADORING 3. The combined result is therefore dominated by pediatric participants. It should not be presented as a study specifically of women in midlife or after menopause.⁴

The May 2025 label covers atopic dermatitis in adults and children aged two or older, with once-daily application. It excludes oral, eye and intravaginal use. In the eight-week eczema trials, folliculitis was reported in 9% with tapinarof versus 1% with vehicle. New bumps deserve review rather than an automatic assumption that eczema is worsening.⁴

What belongs in an individual stop-and-restart plan?

Ask the clinician how they will judge clearance, whether continued or intermittent treatment fits your history, and which changes should prompt a call. A trial average cannot choose the date to stop a prescription.

Keep separate notes on itch, sleep interruption, visible patches and new bumps. Record the treated sites, application dates and other products used there, so the review can distinguish a return of the original rash from a new reaction.

In “Describe It Before You Sort It” in Skin, Head to Toe, the four-part description records location, appearance and sensation, speed of onset and other body changes. Use those details alongside the prescribing plan. Our adult eczema guide covers the broader diagnosis and treatment discussion.